AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 100 micrograms/ml
Number of subjects: 0
Study 8736322 — intervention group
Group type: COMPARATOR
Intervention: Laser Doppler velocimetry
Number of subjects: 0
Study 8736322 — intervention group
Group type: COMPARATOR
Intervention: Perfusion imager
Number of subjects: 0
Study 8736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dia-Stron reflectance spectrophotometer
Number of subjects: 0
Study 2037387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-FU and PP over protein-A sepharose (group A)
Number of subjects: 30
Study 2037387 — intervention group
Group type: COMPARATOR
Intervention: Combination of 5-FU and PP over sepharose (group B)
Number of subjects: 30
Study 2037387 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (group C)
Number of subjects: 30
Study 7247172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous succinylcholine
Number of subjects: 0
Study 7247172 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular succinylcholine
Number of subjects: 0
Study 30625372 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training only
Number of subjects: 282
Study 30625372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training only
Number of subjects: 282
Study 30625372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (strength + aerobic) training
Number of subjects: 282
Study 28489464 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN by the EnligHTN™ multi-electrode system
Number of subjects: 15
Study 28489464 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment continued (control group)
Number of subjects: 15
Study 24732784 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training once a week (G1)
Number of subjects: 30
Study 24732784 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training twice a week (G2)
Number of subjects: 30
Study 24980226 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine
Number of subjects: 200
Study 24980226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine
Number of subjects: 200
Study 24980226 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 200
Study 24980226 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 200
Study 24980226 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 200
Study 22013957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-G: snack fortified with G-FOS (8 g)
Number of subjects: 61
Study 22013957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-P: fermented-malted finger-millet pancake with soy coconut dip (534 mg calcium/serving)
Number of subjects: 61
Study 22013957 — intervention group
Group type: COMPARATOR
Intervention: Group-C: low calcium rice-flakes snack with calcium carbonate (540 mg)
Number of subjects: 61
Study 20215461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW; 2 mg)
Number of subjects: 258
Study 20215461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW; 2 mg) after switching from exenatide BID
Number of subjects: 258
Study 18410607 — intervention group
Group type: EXPERIMENTAL
Intervention: FerX‐Ella antireflux stent (n = 22)
Number of subjects: 49
Study 18410607 — intervention group
Group type: COMPARATOR
Intervention: Ultraflex stent with proton pump inhibitors (n = 26)
Number of subjects: 49
Study 18410607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FerX‐Ella and Ultraflex with PPI)
Number of subjects: 49
Study 15835832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral side port orientation
Number of subjects: 87
Study 15835832 — intervention group
Group type: COMPARATOR
Intervention: Cephalad side port orientation
Number of subjects: 87
Study 15835832 — intervention group
Group type: COMPARATOR
Intervention: Caudad side port orientation
Number of subjects: 87
Study 12430779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (0.6 mg folic acid, 0.8 mg B12, and 2.0 mg B6) for 8 weeks
Number of subjects: 40
Study 12430779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12430779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 40
Study 10347289 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty
Number of subjects: 68
Study 10347289 — intervention group
Group type: COMPARATOR
Intervention: Open gastroplasty
Number of subjects: 68
Study 8814371 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 Gy in two fractions (F2)
Number of subjects: 509
Study 8814371 — intervention group
Group type: COMPARATOR
Intervention: 39 Gy in 13 fractions (F13)
Number of subjects: 509
Study 1330574 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril + 25 mg hydrochlorothiazide
Number of subjects: 19
Study 1330574 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 19
Study 3918684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol
Number of subjects: 88
Study 3918684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 3918684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol and Placebo
Number of subjects: 88
Study 3918684 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term hormone replacement (Mestranol)
Number of subjects: 88
Study 31740866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% collagenated bone mix (Group A)
Number of subjects: 19
Study 31740866 — intervention group
Group type: COMPARATOR
Intervention: 90% collagenated bone mix + 10% collagen gel (Group B)
Number of subjects: 19
Study 29903826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol
Number of subjects: 0
Study 29903826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26999985 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT‐MB with prednisolone 20 mg/day for 6 months followed by tapering by 5 mg/2 weeks in 7th and 8th month (Group A)
Number of subjects: 60
Study 26999985 — intervention group
Group type: COMPARATOR
Intervention: MDT‐MB alone for 12 months (Group B)
Number of subjects: 60
Study 26999985 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT‐MB with prednisolone (Group A)
Number of subjects: 60
Study 25164134 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression-cardiopulmonary resuscitation (IAC-CPR)
Number of subjects: 40
Study 25164134 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 40
Study 20932069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clodronic acid 100 mg once weekly (group A)
Number of subjects: 60
Study 20932069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clodronic acid 200 mg every 2 weeks (group B)
Number of subjects: 60
Study 19363970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cure composite (MultiCore Flow)
Number of subjects: 50
Study 19363970 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass-ionomer cement (Fuji II LC)
Number of subjects: 50
Study 17566842 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with hyperthermia (RT + HT)
Number of subjects: 80
Study 17566842 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy alone (RT)
Number of subjects: 80
Study 14684404 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 2:1 relative to iron
Number of subjects: 10
Study 14684404 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 4:1 relative to iron
Number of subjects: 10
Study 14684404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid at molar ratio of 4:1
Number of subjects: 10
Study 14684404 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythorbic acid at molar ratio of 4:1
Number of subjects: 10
Study 14684404 — intervention group
Group type: COMPARATOR
Intervention: Control (no added enhancer)
Number of subjects: 10
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative evaluation of laboratory data and histopathology of the bone marrow
Number of subjects: 0
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Histotopography and cytological appearance of megakaryopoiesis
Number of subjects: 0
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up studies on prefibrotic IMF
Number of subjects: 0
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters (EPO level, thrombocytosis, LAP)
Number of subjects: 0
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow features (megakaryopoiesis, interstitial changes)
Number of subjects: 0
Study 11317959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential examinations for unclassifiable MPDs
Number of subjects: 0
Study 8398496 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 9
Study 8398496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 8398496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg)
Number of subjects: 9
Study 8398496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2427837 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 16
Study 2427837 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 600 mg
Number of subjects: 16
Study 2427837 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 16
Study 2427837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29847509 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimens
Number of subjects: 820
Study 29847509 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma bilirubin concentration
Number of subjects: 820
Study 27418968 — intervention group
Group type: COMPARATOR
Intervention: MDCO-216 (ApoA-1 Milano/POPC) infusion at doses ranging from 5 to 40 mg/kg
Number of subjects: 48
Study 27418968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24755132 — intervention group
Group type: EXPERIMENTAL
Intervention: AMOXIL® (reference formulation)
Number of subjects: 25
Study 24755132 — intervention group
Group type: EXPERIMENTAL
Intervention: AMOXI‐PED® (test formulation)
Number of subjects: 25
Study 24079062 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake up
Number of subjects: 30
Study 24079062 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 30
Study 24079062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20386601 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for reducing incidence of porcine cysticercosis; duration: 2-9 months (median 4 months); method: lingual examination and antigen ELISA.
Number of subjects: 784
Study 20386601 — intervention group
Group type: COMPARATOR
Intervention: Control group data from 21 of the 42 villages; method: lingual examination.
Number of subjects: 784
Study 20386601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel pigs provided to 295 households; method: reassessment for cysticercosis incidence.
Number of subjects: 784
Study 19033002 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher loading and initial maintenance dose of clopidogrel (600 mg loading dose on day 1 followed by 150 mg once daily on days 2 to 7, followed by 75 mg once daily on days 8-30)
Number of subjects: 18000
Study 19033002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ASA (300-325 mg daily)
Number of subjects: 18000
Study 19033002 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose regimen of clopidogrel (300 mg loading dose on day 1, followed by 75 mg once daily on days 2-30)
Number of subjects: 18000
Study 19033002 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ASA (75-100 mg daily)
Number of subjects: 18000
Study 19033002 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher loading and initial maintenance dose of clopidogrel
Number of subjects: 18000
Study 19033002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ASA
Number of subjects: 18000
Study 19033002 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose regimen of clopidogrel
Number of subjects: 18000
Study 19033002 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ASA
Number of subjects: 18000
Study 16126801 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX‐I
Number of subjects: 105
Study 16126801 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX‐II
Number of subjects: 105
Study 14568740 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralising antibodies positive periods
Number of subjects: 541
Study 14568740 — intervention group
Group type: COMPARATOR
Intervention: Neutralising antibodies negative periods
Number of subjects: 541
Study 14568740 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-negative at 12 months
Number of subjects: 541
Study 14568740 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of neutralising antibodies
Number of subjects: 541
Study 10625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild resuscitative hypothermia (32 to 34 degrees C core temperature) for at least 24 hours after cardiac arrest.
Number of subjects: 27
Study 10625721 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 27
Study 9367476 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide
Number of subjects: 24
Study 9367476 — intervention group
Group type: COMPARATOR
Intervention: 10 ppm inhaled nitric oxide (after 24 h of conventional therapy)
Number of subjects: 24
Study 9367476 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 24
Study 9367476 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide (initial treatment)
Number of subjects: 24
Study 1315121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 84
Study 1315121 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 84
Study 2942707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 210
Study 2942707 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 210
Study 2942707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 210
Study 2942707 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 210
Study 28980293 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet intervention (n = 69)
Number of subjects: 131
Study 28980293 — intervention group
Group type: COMPARATOR
Intervention: Standard recommendations (Control group, n = 62)
Number of subjects: 131
Study 27632909 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g of salmon twice weekly
Number of subjects: 19
Study 27632909 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 g of salmon twice weekly
Number of subjects: 19
Study 27632909 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 g of salmon twice weekly
Number of subjects: 19
Study 24684171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-Train stimulation within the pedicle track using a ball-Tipped probe and electromyography from lower limb muscles
Number of subjects: 71
Study 24684171 — intervention group
Group type: COMPARATOR
Intervention: Direct screw stimulation and electromyogram response from intercostal, abdominal, or lower limb muscles
Number of subjects: 71
Study 23921761 — intervention group
Group type: EXPERIMENTAL
Intervention: IV CITX (5‐fluorouracil 500 mg/m(2) weekly for 24 weeks, mitomycin‐C 8 mg/m(2) every 6 weeks × 4)
Number of subjects: 82
Study 23921761 — intervention group
Group type: COMPARATOR
Intervention: PO CITX (uracil-ftorafur (UFT) 400‐600 mg/day for 12 months)
Number of subjects: 82
Study 21345243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 67
Study 21345243 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity walking
Number of subjects: 67
Study 20533217 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex micronutrient supplement
Number of subjects: 106
Study 16414385 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT plus PTA
Number of subjects: 23
Study 16414385 — intervention group
Group type: COMPARATOR
Intervention: BMT plus supervised exercise
Number of subjects: 23
Study 16414385 — intervention group
Group type: COMPARATOR
Intervention: BMT alone
Number of subjects: 23
Study 15250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-containing sip feed (150 kcal, 2.0 g fibre per 100 ml)
Number of subjects: 60
Study 15250846 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free sip feed (control)
Number of subjects: 60
Study 11240837 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-based care (n = 193)
Number of subjects: 381
Study 11240837 — intervention group
Group type: COMPARATOR
Intervention: Housestaff care (n = 188)
Number of subjects: 381
Study 9052293 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 200
Study 9052293 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 200
Study 8379600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and didanosine
Number of subjects: 69
Study 8379600 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone (600 mg/d)
Number of subjects: 69
Study 8379600 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 69
Study 8379600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens using the same zidovudine dose
Number of subjects: 69
Study 2429818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 24
Study 2429818 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200
Number of subjects: 24
Study 28726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention for depression
Number of subjects: 302
Study 28726086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study 28726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group over time
Number of subjects: 302
Study 28726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose depression remitted
Number of subjects: 302
Study 26803356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 108
Study 26803356 — intervention group
Group type: COMPARATOR
Intervention: Recombinant regular human insulin (RHI)
Number of subjects: 108
Study 24895799 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT), 7.5 g/day, p.o.
Number of subjects: 54
Study 24895799 — intervention group
Group type: COMPARATOR
Intervention: Control group (lactobacillus preparation, 3g/day, p.o.)
Number of subjects: 54
Study 22935955 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh pharmacokinetic model
Number of subjects: 90
Study 22935955 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider pharmacokinetic model
Number of subjects: 90
Study 22935955 — intervention group
Group type: COMPARATOR
Intervention: Both models
Number of subjects: 90
Study 20697547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens including oxaliplatin, irinotecan, and 5-Fluorouracil (5-FU)
Number of subjects: 1700
Study 20697547 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy regimens
Number of subjects: 1700
Study 18664026 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test
Number of subjects: 36
Study 18664026 — intervention group
Group type: COMPARATOR
Intervention: Coronary atherosclerosis plaque volume
Number of subjects: 36
Study 18664026 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil counts
Number of subjects: 36
Study 18664026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte counts
Number of subjects: 36
Study 15884029 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 167
Study 15884029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chosen music
Number of subjects: 167
Study 15884029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and chosen music
Number of subjects: 167
Study 15884029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study 12822543 — intervention group
Group type: EXPERIMENTAL
Intervention: Blatella germanica (Bg) bronchial challenge
Number of subjects: 25
Study 12822543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution) bronchial challenge
Number of subjects: 25
Study 11798658 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4mg qd)
Number of subjects: 52
Study 11798658 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg tid)
Number of subjects: 52
Study 9177646 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed feedback every two months in the form of mailed computer-generated summaries containing mean ratings and written comments.
Number of subjects: 44
Study 9177646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback).
Number of subjects: 44
Study 1929090 — intervention group
Group type: EXPERIMENTAL
Intervention: IAL left in situ
Number of subjects: 60
Study 1929090 — intervention group
Group type: COMPARATOR
Intervention: IAL removed
Number of subjects: 60
Study 1929090 — intervention group
Group type: COMPARATOR
Intervention: Healon removed
Number of subjects: 60
Study 6356899 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (median daily doses of 600 mg)
Number of subjects: 74
Study 6356899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6356899 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 74
Study 30739001 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐month Peer‐Led, Empowerment‐based Approach to Self‐management Efforts in Diabetes (PLEASED) program with 12 weekly contacts in the first 3 months and 18 biweekly contacts over the last 9 months.
Number of subjects: 197
Study 30739001 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study 28361739 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT high (>6 g/day)
Number of subjects: 30